



Verona Pharma

29 December 2016

VERONA PHARMA PLC - Issue of Equity

PR Newswire

London, December 29

Verona Pharma plc

("Verona Pharma" or the "Company")

Exercise of Options

Verona Pharma plc (AIM: VRP), the drug development company focused on first-in-class medicines to treat respiratory diseases, announces that it has issued 2,000,000 new ordinary shares in the capital of the Company (the "New Shares") following an exercise of share options by a former employee. Application has been made to the London Stock Exchange for the New Shares to be admitted to trading on AIM, with dealings expected to commence on 6 January 2017 ("Admission").

Following Admission, the Company will have a total of 2,568,053,160 Ordinary Shares in issue each carrying one voting right. The Company does not hold any Ordinary Shares in Treasury. This figure of 2,568,053,160 Ordinary Shares may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the share capital of the Company under the FCA's Disclosure Guidance and Transparency Rules.

For further information please contact:

Verona Pharma plc

**Tel: +44 (0)20 3283
4200**

Jan-Anders Karlsson, Chief Executive Officer

N+1 Singer (Nominated Adviser and Broker)

**Tel: +44 (0)20 7496
3000**

Aubrey Powell/James White

FTI Consulting

**Tel: +44 (0)20 3727
1000**

Simon Conway/Stephanie Cuthbert/Natalie Garland-Collins

For further information please contact: Verona Pharma plc

Verona Pharma plc

Jan-Anders Karlsson, CEO
Tel: +44 (0)20 3283 4200

info@veronapharma.com

N+1 Singer (Nominated Adviser and UK Broker)

Aubrey Powell / James White

Tel: +44 (0)20 7496 3000

FTI Consulting

Simon Conway / Stephanie Cuthbert / Natalie Garland-Collins

Tel: +44 (0)20 3727 1000

veronapharma@fticonsulting.com

ICR, Inc. (US Media and Investor enquiries)

James Heins

Tel: +1 203-682-8251

James.Heins@icrinc.com

Stephanie Carrington

Tel. +1 646-277-1282

Stephanie.Carrington@icrinc.com

About Verona Pharma plc

Verona Pharma is a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapeutics for the treatment of respiratory diseases with significant unmet medical needs. Verona Pharma's product candidate, RPL554, is a first-in-class, inhaled, dual inhibitor of the enzymes phosphodiesterase 3 and 4 that acts as both a bronchodilator and an anti-inflammatory agent in a single compound. In clinical trials, treatment with RPL554 has been observed to result in statistically significant improvements in lung function as compared to placebo and has shown clinically meaningful and statistically significant improvements in lung function when added to two commonly used bronchodilators as compared to either bronchodilator administered as a single agent. RPL554 has also shown anti-inflammatory effects and been well tolerated in clinical trials. Verona Pharma is developing RPL554 for the treatment of chronic obstructive pulmonary disease (COPD), cystic fibrosis, and potentially asthma.

Forward Looking Statements

This press release contains forward-looking statements. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements.

These forward-looking statements are based on management's current expectations. These statements are neither promises nor guarantees, but involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from our expectations expressed or implied by the forward-looking statements, including, but not limited to, the development of DPI and MDI formulations of RPL554 and the potential for these formulations to increase the market opportunity for the product, if approved.

These and other important factors could cause actual results to differ materially from those indicated by the forward-looking statements made in this press release. Any such forward-looking statements represent management's estimates as of the date of this press release. While we may elect to update such forward-looking statements at some point in the future, we disclaim any obligation to do so, even if subsequent events cause our views to change. These forward-looking statements should not be relied upon as representing our views as of any date subsequent to the date of this press release.